Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     

Australia's Leading Ophthalmic Magazine Since 1975

     Free Sign Up     
News, Lenses

MiSight continues to slow myopia

14/08/2019By Callum Glennen
Share:
Five year results from the world’s longest-running clinical trial of paediatric contact lens wear has shown CooperVision’s MiSight 1 Day lens continues to slow myopia in children, even at older ages.

The data is the latest release from CooperVision’s quantified study comparing the effectiveness of MiSight 1 Day lenses to an equivalent single vision 1-day lens.

According to the company, new data has shown children who started MiSight 1 Day treatment at a slightly older age demonstrated the same slowed rate of progression as those who commenced wear at the beginning of the study.

Children who are part of this second group – the original control group who were refit with MiSight 1 day at the 36 month mark – matched the children who had been wearing MiSight for the entire duration of the study in spherical equivalent refractive error (0.17D) and axial length (0.07mm) during year five.

In addition, the study reported minimal adverse events, and visual performance remained excellent between both groups.

Paul Chamberlain
Paul Chamberlain
“The mirrored slowed progression across both groups suggests that myopia progression with MiSight 1 Day lenses is more dependent on age of the patient than their baseline myopia or length of time under treatment”
Paul Chamberlain, CooperVision

“The mirrored slowed progression across both groups suggests that myopia progression with MiSight 1 Day lenses is more dependent on age of the patient than their baseline myopia or length of time under treatment,” Dr Paul Chamberlain, director of research programs for CooperVision, said.

“The children more recently entering treatment are progressing at the same rate as those completing their fifth year of MiSight 1 Day wear. This information can help practitioners as they consider treating slightly older kids than studied in part one of the trial.”

CooperVision reports that the results are unparalleled, with no other prospective randomised controlled study looking at the same parameters offering such conclusive data.

Brien Holden Vision Institute donation

At the same time, CooperVision also announced it is on track to donate up to US$500,000 (AU$736,360) from its MiSight 1 Day sales to the Brien Holden Vision Institute (BHVI) Foundation’s Our Children’s Vision campaign by the end of 2020.

“We firmly believe having strong partnerships in place can get us further than any individual effort,” Ms Yvette Waddell, CEO of BHVI Foundation, said.

“The assistance we’re receiving from CooperVision will help us reach more children and provide greater access to eye health services in underserved communities, as well as help us advocate on behalf of a vulnerable demographic to ensure child eye health is integrated into country and education policies.”

Dr Juan Carlos Aragón, president of CooperVision’s specialty eyecare division, said the world’s growing myopia epidemic threatens economic productivity and has social implications.

“That is why we are working diligently on the best ways to help manage the progression of the condition in children to help them see clearly, minimise the risk of potential ocular disease related to high levels of myopia and live brightly.”

 

More reading:

Myopia: A new opportunity
Combatting Myopia proves to be a strong drawcard





rectangle
advertisement
Editor's Suggestion
Hot Stories

rectangle
advertisement


OR
 

Subscribe for Insight in your Inbox

Get Insight with the latest in industry news, trends, new products, services and equipment!